Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$27.60M

FY 2025 · Annual

Investing Cash Flow

-$8,232.00

FY 2025 · Annual

Financing Cash Flow

$19.37M

FY 2025 · Annual

+192.0% YoY

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.3M)(24.84M)(27.75M)(31.71M)(39.46M)
Depreciation & Amortization452.07K392K403K424K96.05K
Deferred Income Tax408.56K0000
Stock-Based Compensation3.83M2.38M2.07M2.72M4.26M
Change in Working Capital(907.99K)391K1.77M3.54M1.62M
Accounts Receivables(776.39K)345K506K(53K)4.03M
Inventory00000
Accounts Payables00000
Other Working Capital(131.59K)46K1.26M3.59M(2.41M)
Other Non-Cash Items91.73K(1.68M)(4.93M)(1.94M)5.89M
Operating Cash Flow(22.43M)(23.36M)(28.45M)(26.97M)(27.6M)
Capital Expenditures(285.95K)(55K)(8K)(239K)(8.23K)
Acquisitions (Net)00000
Purchases of Investments0(20.35M)000
Sales of Investments0020.23M00
Other Investing Activities0(20.35K)000
Investing Cash Flow(285.95K)(20.4M)20.22M(239K)(8.23K)
Debt Repayment(366K)(381K)(407K)(348K)0
Common Stock Issued32.91M12.57M31.62M6.92M19.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities469.68K12K781K65K(37.05K)
Financing Cash Flow33.02M12.21M31.99M6.64M19.37M
Effect of Forex Changes(253.25K)1.96M(522K)1.6M166.03K
Net Change in Cash10.04M(29.6M)23.25M(18.97M)(8.06M)
Free Cash Flow(22.72M)(23.41M)(28.46M)(27.21M)(27.6M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.5M
+ D&A$96.0K
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
+ Working Capital$1.6M
+ Other Non-Cash$5.9M
= Operating Cash Flow-$27.6M
- Capex-$8.2K
= Free Cash Flow-$27.6M

Analysis

FY2025 free cash flow is -$27.6M. FCF conversion is 69.9% of net income. Operating cash flow was -$27.6M, with capex of -$8.2K. The largest bridge item is Other Non-Cash at $5.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 20, 2026
8-KCurrent reportOct 14, 2026
8-KCurrent reportOct 13, 2026
DEFA14ADEFA14A filingOct 6, 2026
DEF 14ADEF 14A filingOct 6, 2026

Does ONCY generate free cash flow?

Oncolytics Biotech Inc. (ONCY) generated -$27.60M of free cash flow in fiscal 2025.

How much operating cash flow does ONCY produce?

Operating cash flow was -$27.60M, before capital expenditures of $8,232.00.